Anavex Life Sciences (AVXL) Share-based Compensation (2010 - 2025)
Anavex Life Sciences recorded quarterly Share-based Compensation of $1.1 million in Q4 2025, down 84.73% quarter-over-quarter from $7.2 million in Q3 2025, and down 46.13% year-over-year from $2.1 million in Q4 2024.
Anavex Life Sciences' Share-based Compensation history runs 16 years deep, the most recent figure standing at $1.1 million for Q4 2025.
- In Q4 2025, Share-based Compensation fell 46.13% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $14.1 million (down 25.81% YoY), while the FY2025 annual figure was $11.5 million, up 22.37% from the prior year.
- Share-based Compensation came in at $1.1 million for Q4 2025 at Anavex Life Sciences, down from $7.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $7.4 million in Q2 2024 to a low of $1.1 million in Q4 2025.
- A 5-year average of $3.9 million and a median of $3.9 million in 2021 frame the typical range for Share-based Compensation.
- Across the five-year window, Share-based Compensation jumped 372.39% in 2021 and tumbled 57.25% in 2023, its largest moves.
- Anavex Life Sciences' Share-based Compensation stood at $3.9 million in 2021, then surged by 36.79% to $5.3 million in 2022, then sank by 57.25% to $2.3 million in 2023, then slipped by 10.1% to $2.1 million in 2024, then plunged by 46.13% to $1.1 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.1 million, $7.2 million, and $4.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Anavex Life Sciences | 266.20 Mn | 134.45 Mn | - | 1.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.11 Mn |
| Dec 31, 2025 | 1.11 Mn |
| Sep 30, 2025 | 7.25 Mn |
| Sep 30, 2025 | 7.25 Mn |
| Jun 30, 2025 | 4.32 Mn |
| Jun 30, 2025 | 4.32 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.45 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 6.94 Mn |
| Sep 30, 2024 | 6.94 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Jun 30, 2024 | 7.40 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Mar 31, 2024 | 2.65 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Dec 31, 2023 | 2.29 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Jun 30, 2023 | 3.87 Mn |
| Mar 31, 2023 | 3.97 Mn |
| Mar 31, 2023 | 3.97 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Sep 30, 2022 | 6.06 Mn |
| Sep 30, 2022 | 6.06 Mn |
| Jun 30, 2022 | 3.99 Mn |
| Jun 30, 2022 | 3.99 Mn |
| Mar 31, 2022 | 4.44 Mn |
| Mar 31, 2022 | 4.44 Mn |
| Dec 31, 2021 | 3.91 Mn |
| Dec 31, 2021 | 3.91 Mn |
| Sep 30, 2021 | 3.12 Mn |
| Sep 30, 2021 | 3.12 Mn |
| Jun 30, 2021 | 2.29 Mn |
| Jun 30, 2021 | 2.29 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 939,314.00 |
| Dec 31, 2020 | 939,314.00 |
| Sep 30, 2020 | 660,600.00 |
| Sep 30, 2020 | 660,600.00 |
| Jun 30, 2020 | 1.25 Mn |
| Jun 30, 2020 | 1.25 Mn |
| Mar 31, 2020 | 1.70 Mn |
| Mar 31, 2020 | 1.70 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Dec 31, 2019 | 1.26 Mn |
| Sep 30, 2019 | 1.24 Mn |
| Sep 30, 2019 | 1.24 Mn |
| Jun 30, 2019 | 1.23 Mn |
| Jun 30, 2019 | 1.23 Mn |
| Mar 31, 2019 | 1.89 Mn |
| Mar 31, 2019 | 1.89 Mn |
| Dec 31, 2018 | 2.07 Mn |
| Dec 31, 2018 | 2.07 Mn |
| Sep 30, 2018 | 1.49 Mn |
| Sep 30, 2018 | 1.49 Mn |
| Jun 30, 2018 | 1.68 Mn |
| Jun 30, 2018 | 1.68 Mn |
| Mar 31, 2018 | 1.23 Mn |
| Mar 31, 2018 | 1.23 Mn |
| Dec 31, 2017 | 1.12 Mn |
| Dec 31, 2017 | 1.12 Mn |
| Sep 30, 2017 | 1.12 Mn |
| Sep 30, 2017 | 1.12 Mn |
| Jun 30, 2017 | 1.16 Mn |
| Jun 30, 2017 | 1.16 Mn |
| Mar 31, 2017 | 968,893.00 |
| Mar 31, 2017 | 968,893.00 |
| Dec 31, 2016 | 889,267.00 |
| Dec 31, 2016 | 889,267.00 |
| Sep 30, 2016 | 3.79 Mn |
| Sep 30, 2016 | 3.79 Mn |
| Jun 30, 2016 | 230,239.00 |
| Jun 30, 2016 | 230,239.00 |
| Mar 31, 2016 | 222,690.00 |
| Mar 31, 2016 | 222,690.00 |
| Dec 31, 2015 | 826,020.00 |
| Dec 31, 2015 | 826,020.00 |
| Sep 30, 2015 | 1.37 Mn |
| Sep 30, 2015 | 1.37 Mn |
| Jun 30, 2015 | 11,283.00 |
| Jun 30, 2015 | 11,283.00 |
| Dec 31, 2014 | 15,362.00 |
| Dec 31, 2014 | 15,362.00 |
| Sep 30, 2014 | 628,336.00 |
| Sep 30, 2014 | 628,336.00 |
| Jun 30, 2014 | 9,589.00 |
| Jun 30, 2014 | 9,589.00 |
| Sep 30, 2013 | 1.00 Mn |
| Sep 30, 2013 | 1.00 Mn |
| Jun 30, 2012 | 98,800.00 |
| Jun 30, 2012 | 98,800.00 |
| Mar 31, 2012 | 80,144.00 |
| Mar 31, 2012 | 80,144.00 |
| Dec 31, 2011 | 123,264.00 |
| Dec 31, 2011 | 123,264.00 |
| Sep 30, 2011 | 257,747.00 |
| Sep 30, 2011 | 257,747.00 |
| Jun 30, 2011 | 159,186.00 |
| Jun 30, 2011 | 159,186.00 |
| Mar 31, 2011 | 668,479.00 |
| Mar 31, 2011 | 668,479.00 |
| Dec 31, 2010 | 187,750.00 |
| Dec 31, 2010 | 187,750.00 |
| Sep 30, 2010 | 145,917.00 |
| Sep 30, 2010 | 145,917.00 |